)
)
)
Targazyme, Inc.
TargaZyme is an award-winning ($60MM+), Phase 3 ready, FDA SPA awardee Biopharma Company with a novel, patented, derisked enzyme drug candidate TZ 101 targeting a $15B market opportunity. This lead candidate is proven in Phase 2 trials to improve survival of cancer and auto-immune patients undergoing mobilized blood transfusion (Hematopoietic Stem Cell Transplantation) by preventing multiple morbidities that cause patient mortality such as engraftment failure, infections, GvHD, hemorrhaging with the potential to prevent relapse of the disease (i.e enabling longer disease remissions).
TZ 101 is also a cell enabling platform technology proven in human trials to multiply Efficacy & Safety outcomes for cancer and auto-immune diseased patients receiving T-cells, Tregs, NK cells, stem cells, blood transfusion etc. Preclinical data points to the potential for TZ 101 to also transform COGS reduction and Manufacturing scalability for blood, T, NK, Treg, stem cell therapies.
Address
CarlsbadCA
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)